CD4+ T Cells Specific for Factor VIII as a Target for Specific Suppression of Inhibitor Production
- 1 January 2001
- book chapter
- Published by Springer Nature
- Vol. 489, 119-134
- https://doi.org/10.1007/978-1-4615-1277-6_11
Abstract
Some hemophilia A patients, when treated with factor VIII (fVIII) products to control bleeding episodes, develop antibodies (Ab) to surface domains of fVIII that are essential for its procoagulant function 1,3 Development of fVIII inhibitors is a serious therapeutic complication that affects 20 – 25% of patients with hemophilia A 1,3 Individuals without congenital fVIII deficiency may also develop pathogenic autoimmune inhibitory Ab to fVIII that cause acquired hemophilia, a rare yet severe bleeding disorder (4,5 ). FVIII inhibitors are high affinity IgG, and their synthesis requires the intervention of fVIII specific CD4+ T helper cells.Keywords
This publication has 90 references indexed in Scilit:
- The Th1/Th2 paradigmImmunology Today, 1997
- Late Complications of Immune Deviation Therapy in a Nonhuman PrimateScience, 1996
- Epidemiology of Inhibitors in Haemophilia AVox Sanguinis, 1996
- TSH Receptor Sequences Recognized by CD4+T Cells in Graves' Disease Patients and Healthy ControlsJournal of Autoimmunity, 1995
- Minireview The role of anergy in peripheral T cell unresponsivenessLife Sciences, 1994
- Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies.Journal of Clinical Investigation, 1994
- Myasthenia gravis: recognition of a human autoantigen at the molecular levelImmunology Today, 1993
- Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cellsEuropean Journal of Immunology, 1989
- Antigen-specific interaction between T and B cellsNature, 1985
- Structure of human factor VIIINature, 1984